ArticleMolecular therapy. Methods & clinical development2020
Methods Matter: Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct Vectors.
Abstract read
In one paragraph
Article in Molecular therapy. Methods & clinical development, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis.Frontiers in immunology · 2022Pooled it
- Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays.International journal of molecular sciences · 2020Pooled it
- Systematic evaluation of BBB-penetrant AAV capsids in marmosets identifies VCAP-102 as a highly efficient brain-transducing capsid.Molecular therapy. Advances · 2026Article
- AAV vector production in suspension cells using PEI transfection and sodium butyrate with orthogonal assessment of function and quality.Molecular therapy. Advances · 2026Article
- Combined Plasmid Redesign and Transfection Optimization Significantly Increases Upstream AAV Titers While Maintaining Vector Quality and In Vivo Potency.Microorganisms · 2026Article
- AAV immuno-gene therapy platform delivering vectorized cytokines defines a new modality for high-grade glioma treatment.Molecular therapy. Oncology · 2026Article
- Role of viral protein ratio in the structure and separation of empty and full adeno-associated virus capsids: A molecular dynamics study.Molecular therapy. Advances · 2026Article
- Manufacture of adeno-associated virus vectors by a novel human-derived cell line HAT and comprehensive evaluation of the vectors.Molecular therapy. Advances · 2026Article
- A Fed-batch Process for the Production of Recombinant Adeno-associated Virus (rAAV) Vectors Using the Sf9-Rhabdovirus-negative Cell Line.Current pharmaceutical biotechnology · 2026Article
- Current regulatory requirements for assessment of immunogenicity for gene therapy medicinal products.Cell reports. Medicine · 2025Review
- Development of high-throughput analytical methods for characterization and quantitation of rAAV genome integrity.Molecular therapy. Methods & clinical development · 2025Article
- Characterization of difficult-to-remove host cell proteins in adeno-associated virus downstream processing.Molecular therapy. Methods & clinical development · 2025Article
- AAV capsid prioritization in normal and steatotic human livers maintained by machine perfusion.Nature biotechnology · 2025Article
- Development of LC-MS methods for AAV capsid protein quantification and host cell protein profiling.Molecular therapy. Methods & clinical development · 2025Article
- Analytical dissection of minor glycoforms and glycoprotein associations in rAAV preparations by multimodal glycoproteomics.Analytical and bioanalytical chemistry · 2025Article
- A clinician's guide to AAV production - How manufacturing platforms shape vector properties.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2025Article
- Investigating the Immunogenic Potential of Variations in Host Cell Protein Levels in Clinical-Grade AAV8 Products.Investigative ophthalmology & visual science · 2025Article
- Combination of hydrophilic interaction liquid chromatography and top-down mass spectrometry for characterisation of adeno-associated virus capsid proteins.Analytical and bioanalytical chemistry · 2025Article
- AAV vector development, back to the future.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Chromatography in Downstream Processing of Recombinant Adeno-Associated Viruses: A Review of Current and Future Practises.Biotechnology and bioengineering · 2025Review
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Neil G RumachikDepartment of Chemistry, Stanford University, Stanford, CA 94305, USA.
Stacy A MalakerDepartment of Chemistry, Stanford University, Stanford, CA 94305, USA.
Nicole PoweleitDepartment of Medicine, University of California San Francisco, San Francisco, CA 94305, USA.
Lucy H MaynardGenome Engineering, Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.
Christopher M AdamsVincent Coates Foundation Mass Spectrometry Laboratory, Stanford University, Stanford, CA 94305, USA.
Ryan D LeibVincent Coates Foundation Mass Spectrometry Laboratory, Stanford University, Stanford, CA 94305, USA.
Giana CiroliaGenome Engineering, Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.
Dennis ThomasCryo-EM Core Facility, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
Susan StamnesViral Vector Core, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA.
Kathleen HoltViral Vector Core, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA.
Patrick SinnViral Vector Core, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA.
Andrew P MayGenome Engineering, Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.
Nicole K PaulkGenome Engineering, Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.
Funding
Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0MVector CoreP01HL051670 · NHLBI · UNIVERSITY OF IOWA · PI MCCRAY, PAUL B · 1993 to 2019
$36.5MVector Core-Core 2P30DK054759 · NIDDK · UNIVERSITY OF IOWA · PI Amy Leanne Ryan · 1998 to 2026
$30.5MTranscriptional Networks During Cardiac DifferentiationP01HL089707 · NHLBI · J. DAVID GLADSTONE INSTITUTES · PI SRIVASTAVA, DEEPAK · 2008 to 2017
$20.4MMicrobial Pathogenesis and Host DefenseT32AI060537 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joanne N. Engel · 2004 to 2026
$6.5MJAX-Gladstone, SCGE Disease Models Studies SupplementU01ES032673 · NIEHS · J. DAVID GLADSTONE INSTITUTES · PI CONKLIN, BRUCE R · 2020 to 2022
$2.4MMaking glycoproteomics via mass spectrometry more accessible to the greater scientific communityU01CA207702 · NCI · STANFORD UNIVERSITY · PI BERTOZZI, CAROLYN, PITTERI, SHARON · 2016 to 2019
$1.9MOvercoming sexually dimorphic barriers to viral gene therapy for treating genetic liver diseases.K01DK107607 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PAULK, NICOLE K · 2016 to 2020
$782kHuman microtissues for in situ detection and functional measurement of adverse consequences caused by genome editingU01HL145795 · NHLBI · J. DAVID GLADSTONE INSTITUTES · PI MCDEVITT, TODD C · 2018 to 2018
$742kAcquisition of Covaris E220 and Sciclone G3 systems for high throughput sequencinS10OD010786 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI COMAI, LUCA · 2012 to 2012
$311kAn enzymatic approach to study cancer-associated cell-surface glycoproteins: exploration of mucin-degrading bacterial metalloproteasesF32GM126663 · NIGMS · STANFORD UNIVERSITY · PI MALAKER, STACY ALYSE · 2017 to 2019
$125kNCI NIH HHS P30 CA086862NCI NIH HHS U01 CA207702NHLBI NIH HHS P01 HL051670NHLBI NIH HHS P01 HL089707NHLBI NIH HHS U01 HL145795NIAID NIH HHS T32 AI060537NIDDK NIH HHS K01 DK107607NIDDK NIH HHS P30 DK054759NIEHS NIH HHS U01 ES032673NIGMS NIH HHS F32 GM126663NIH HHS S10 OD010786
Abstract
Different approaches are used in the production of recombinant adeno-associated virus (rAAV). The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of
Indexed as
AAVadeno-associated virusbaculovirus-Sf9capsidhumanmass spectrometrymethylationpost-translational modificationpotencyPTM
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.